Seattle Genetics investors retreat on robust Adcetris pricing
This article was originally published in Scrip
Executive Summary
While investors were fired up on 19 August about Seattle Genetics' early win for its Hodgkin's lymphoma (HL) drug Adcetris (brentuximab vedotin) – driving shares as high as 14.2% – that glee turned to apprehension on 22 August when the Bothell, Washington-based biotech revealed the $13,500 per dosage price (scripintelligence, 22 August 2011).